Influenza virus vaccine liposomal - Parkedale

Drug Profile

Influenza virus vaccine liposomal - Parkedale

Alternative Names: Fluogen liposomal

Latest Information Update: 12 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parkedale Pharmaceuticals
  • Developer Novavax; Parkedale Pharmaceuticals
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 12 Jan 2004 No development reported - Preclinical for Influenza virus infections in USA (unspecified route)
  • 17 Oct 2000 Parkedale has discontinued Fluogen®; it is unclear whether this means that development of the liposomal formulation has also been discontinued
  • 01 Nov 1999 Preclinical development for Influenza virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top